Did brentuximab vedotin’s rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results?
| Prif Awdur: | |
|---|---|
| Fformat: | Erthygl |
| Iaith: | English |
| Cyhoeddwyd: |
Ferrata Storti Foundation
2021-12-01
|
| Cyfres: | Haematologica |
| Mynediad Ar-lein: | https://haematologica.org/article/view/10491 |